NovoCodex Biopharmaceuticals, a subsidiary of Shanghai-listed pharmaceutical major Zhejiang Medicine, has raised 400 million yuan ($62 million) in its Series A round to expedite the development of antibody-drug conjugate (ADC).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
